Charles Schwab Investment Management Inc. Acquires 251,876 Shares of Amgen Inc. (NASDAQ:AMGN)

Charles Schwab Investment Management Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,532,629 shares of the medical research company’s stock after acquiring an additional 251,876 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Amgen were worth $3,393,718,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Smithfield Trust Co raised its position in shares of Amgen by 6.7% during the 3rd quarter. Smithfield Trust Co now owns 3,668 shares of the medical research company’s stock valued at $1,175,000 after purchasing an additional 230 shares during the period. Integrated Investment Consultants LLC lifted its position in Amgen by 97.5% in the third quarter. Integrated Investment Consultants LLC now owns 2,826 shares of the medical research company’s stock worth $911,000 after buying an additional 1,395 shares during the last quarter. Thompson Siegel & Walmsley LLC boosted its stake in shares of Amgen by 7.4% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 41,548 shares of the medical research company’s stock worth $13,387,000 after purchasing an additional 2,871 shares during the period. LPL Financial LLC boosted its position in shares of Amgen by 0.7% during the third quarter. LPL Financial LLC now owns 751,945 shares of the medical research company’s stock valued at $242,284,000 after buying an additional 4,999 shares during the period. Finally, Tradewinds LLC. grew its position in Amgen by 5.6% in the 3rd quarter. Tradewinds LLC. now owns 2,655 shares of the medical research company’s stock valued at $856,000 after acquiring an additional 141 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

AMGN stock opened at $285.11 on Thursday. Amgen Inc. has a 1 year low of $260.68 and a 1 year high of $346.85. The firm has a market capitalization of $153.26 billion, a PE ratio of 36.86, a price-to-earnings-growth ratio of 2.50 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The business has a 50 day simple moving average of $318.08 and a 200-day simple moving average of $318.22.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the firm earned $4.96 EPS. Equities research analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.16%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of research reports. Truist Financial lowered shares of Amgen from a “buy” rating to a “hold” rating and raised their target price for the stock from $320.00 to $333.00 in a research report on Monday, October 14th. Barclays raised their price target on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Citigroup started coverage on Amgen in a research report on Thursday, November 14th. They set a “neutral” rating and a $335.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.